Nadia Dehbokri1,2, Gholamreza Noorazar3, Aida Ghaffari4, Gita Mehdizadeh1,2, Parvin Sarbakhsh5, Saba Ghaffary6. 1. Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran. 2. Department of Pharmacotherapy, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 3. Research Center of Psychiatry and Behavioral Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. 4. Pediatrics Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 5. Road Traffic Injury Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 6. Department of Pharmacotherapy, Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ghaffarys@tbzmed.ac.ir.
Abstract
BACKGROUND: In this research the symptom improvement of attention-deficit hyperactivity disorder (ADHD) of children was assessed by oral vitamin D administration in Tabriz, Iran. METHODS: In this double-blind, randomized clinical trials, 96 children (2-18 years) were enrolled to placebo and vitamin D groups. Children took vitamin D pearl (50,000 IU/week) or placebo for 6 weeks. Children, who had the change in methylphenidate dosage and received any anticonvulsants and corticosteroids were excluded from the research. ADHD symptoms were diagnosed by Conners parent rating scale (CPRS) test at baseline and after intervention. ADHD Conners divided into inattention (IA), hyperactivity/impulsivity (H/I) and combination type (C) subscales. Vitamin D serum level was assessed at baseline and after 8 weeks in both groups. RESULTS: The differences between CPRS and its subscales were not significant at baseline (P > 0.05). The Conners IA score was decreased in vitamin D group (P < 0.05; adjusted with age and baseline values). ADHD Conners and all subscale scores reduced remarkably after intervention in patients with insufficient level of vitamin D compared to placebo (P < 0.05). CONCLUSIONS:Oral vitamin D improved ADHD symptoms with a particular effect on inattention symptoms. In addition, symptoms related to all subscales were improved remarkably in patients with insufficient level of vitamin D. Vitamin D treatment in children with ADHD could be considered due to the expand benefit of vitamin D in body.
RCT Entities:
BACKGROUND: In this research the symptom improvement of attention-deficit hyperactivity disorder (ADHD) of children was assessed by oral vitamin D administration in Tabriz, Iran. METHODS: In this double-blind, randomized clinical trials, 96 children (2-18 years) were enrolled to placebo and vitamin D groups. Children took vitamin D pearl (50,000 IU/week) or placebo for 6 weeks. Children, who had the change in methylphenidate dosage and received any anticonvulsants and corticosteroids were excluded from the research. ADHD symptoms were diagnosed by Conners parent rating scale (CPRS) test at baseline and after intervention. ADHD Conners divided into inattention (IA), hyperactivity/impulsivity (H/I) and combination type (C) subscales. Vitamin D serum level was assessed at baseline and after 8 weeks in both groups. RESULTS: The differences between CPRS and its subscales were not significant at baseline (P > 0.05). The Conners IA score was decreased in vitamin D group (P < 0.05; adjusted with age and baseline values). ADHD Conners and all subscale scores reduced remarkably after intervention in patients with insufficient level of vitamin D compared to placebo (P < 0.05). CONCLUSIONS: Oral vitamin D improved ADHD symptoms with a particular effect on inattention symptoms. In addition, symptoms related to all subscales were improved remarkably in patients with insufficient level of vitamin D. Vitamin D treatment in children with ADHD could be considered due to the expand benefit of vitamin D in body.
Authors: L Kent; U Doerry; E Hardy; R Parmar; K Gingell; Z Hawi; A Kirley; N Lowe; M Fitzgerald; M Gill; N Craddock Journal: Mol Psychiatry Date: 2002 Impact factor: 15.992
Authors: Thomas H J Burne; Axel Becker; Jillanne Brown; Darryl W Eyles; Alan Mackay-Sim; John J McGrath Journal: Behav Brain Res Date: 2004-10-05 Impact factor: 3.332
Authors: James P Kesby; Xiaoying Cui; Jonathan O'Loan; John J McGrath; Thomas H J Burne; Darryl W Eyles Journal: Psychopharmacology (Berl) Date: 2009-11-18 Impact factor: 4.530
Authors: Kumar T Peeyush; Balakrishnan Savitha; Antony Sherin; T R Anju; Paul Jes; C S Paulose Journal: Pharmacol Biochem Behav Date: 2010-01-22 Impact factor: 3.533
Authors: D W Eyles; F Feron; X Cui; J P Kesby; L H Harms; P Ko; J J McGrath; T H J Burne Journal: Psychoneuroendocrinology Date: 2009-12 Impact factor: 4.905